Dr. James OhrMedical Oncologist and Hematologist
Dr. James Paul Ohr is a medical oncologist and hematologist with extensive experience treating a wide variety of malignancies at the UPMC Hillman Cancer Center in Pittsburgh.
Get to Know Dr. James Paul Ohr
Dr. James Ohr is a medical oncologist and hematologist playing a key role at the Mesothelioma Specialty Care Center at UPMC Hillman Cancer Center in Pittsburgh.
Ohr specializes in peritoneal carcinomas such as mesothelioma, along with gastrointestinal malignancies and head and neck cancers. He treats patients with peritoneal mesothelioma, a rare cancer in the abdominal cavity caused primarily by asbestos exposure.
The Hillman Cancer Center, which has more than 70 locations, is the only center in the region designated a National Cancer Institute Comprehensive Cancer Center. It provides care that is unmatched in Western Pennsylvania.
Its reputation often stems from its internationally renowned research, which provides advances in prevention, early detection and novel treatments that make it unique.
Ohr works closely with other mesothelioma doctors, such as oncologist Dr. Antoinette Wozniak and surgeon Dr. James Pingpank, helping provide a multidisciplinary approach to treatment.
Specialties of Dr. James Paul Ohr
- Head and neck cancers
- Peritoneal carcinomas
- Gastrointestinal cancers
- Peritoneal mesothelioma
Dr. James Paul Ohr’s Experience and Education
- UPMC Hillman Cancer Center
- Western Pennsylvania Hospital (Fellowship and Residency)
- Philadelphia College of Osteopathic Medicine (D.O.)
Awards and Certifications
- American Board of Internal Medicine
- Pennsylvania state medical license
Publications of Dr. James Paul Ohr
- Bauman, J.E. et al. (2020, June 11). Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. Cancers.
- Thomas, J. et al. (2020, February 5). Long-Term Patient-Reported Quality of Life After Stereotactic Body Radiation Therapy for Recurrent, Previously-Irradiated Head and Neck Cancer. Frontiers in Oncology.
- Argiris, A. et al. (2019, December). Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. Journal of Clinical Oncology.
- Ling, D.C. et al. (2016, July). Risk of Severe Toxicity According to Site of Recurrence in Patients Treated with Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer. International Journal of Radiation Oncology.